AbbVie Inc. (ABBV)
After hours:
| Previous close | 158.25 |
| Open | 158.98 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's range | 156.36 - 159.70 |
| 52-week range | 134.09 - 175.91 |
| Volume | |
| Avg. volume | 6,411,436 |
| Market cap | 278.734B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 23.83 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.92 (3.74%) |
| Ex-dividend date | 13 Apr 2023 |
| 1y target est | N/A |
- PR Newswire
Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from 30 March - 1 April 2023, supporting practitioners to help patients 'unlock their individuality' in an evolving world. Events include two Allergan Medical Institute (AMI) symposia, Meet the Expert sessions and an interactive exhibition booth that practitioners can explore. Throug
- PR Newswire
AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus
AbbVie (NYSE: ABBV) today announced topline results from a Phase 2 study of upadacitinib (RINVOQ®, 30 mg) given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg), once daily in patients with moderately to severely active systemic lupus erythematosus (SLE).1 The SLEek study met the primary endpoint of SLE Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in the upadacitinib 30
- PR Newswire
Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
AbbVie (NYSE: ABBV) today announced positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab (SKYRIZI®,1200 mg intravenous [IV], at weeks 0, 4 and 8) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis.1 In the study, 20.3% of patients receiving risankizumab achieved clinical remission compared to 6.2% of patients receiving plac
